Attached files
| file | filename |
|---|---|
| EX-99.2 - PRESS RELEASE - Avid Bioservices, Inc. | peregrine_8k-ex9902.htm |
| EX-99.1 - PRESS RELEASE - Avid Bioservices, Inc. | peregrine_8k-ex9901.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2013
PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-17085 | 95-3698422 | ||
| (State of other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
| 14282 Franklin Avenue, Tustin, California 92780 | ||||
| (Address of Principal Executive Offices) | ||||
| Registrant’s telephone number, including area code: (714) 508-6000 | ||||
| Not Applicable | ||||
| (Former name or former address, if changed since last report) | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 3, 2013, Peregrine Pharmaceuticals, Inc. issued a press release reporting final data from its randomized, double-blind, placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
In addition, on June 3, 2013, Peregrine Pharmaceuticals, Inc. also issued a press release reporting interim data from an investigator-sponsored, open-label, Phase I trial evaluating bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer and final data from its company sponsored, open-label, randomized Phase II trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| Exhibit | |
| Number | |
| 99.1 | Press Release issued June 3, 2013, entitled “Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated with Peregrine Pharmaceuticals’ Novel Immunotherapy Bavituximab.” |
| 99.2 | Press Release issued June 3, 2013, entitled “Encouraging Results in Breast and Pancreatic Cancers for Patients Treated with Peregrine’s Novel Immunotherapy Bavituximab Presented at ASCO.” |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PEREGRINE PHARMACEUTICALS, INC. | |
| Date: June 3, 2013 | By: /s/ Paul J. Lytle |
| Paul J. Lytle | |
| Chief Financial Officer |
| 3 |
EXHIBIT INDEX
| Exhibit | |
| Number | Description |
| 99.1 | Press Release issued June 3, 2013, entitled “Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated with Peregrine Pharmaceuticals’ Novel Immunotherapy Bavituximab.” |
| 99.2 | Press Release issued June 3, 2013, entitled “Encouraging Results in Breast and Pancreatic Cancers for Patients Treated with Peregrine’s Novel Immunotherapy Bavituximab Presented at ASCO.” |
| 4 |